ASCO 2008: EGFR Inhibitors in Colorectal Cancer

ASCO 2008 Breast Cancer Update

Updates in the Management of Gynecologic Cancers: A Report from the 39th Annual Meeting of the Society of Gynecologic Oncologists

Bone Loss and Bone Metastases in Breast Cancer: A Report from the 2007 San Antonio Breast Cancer Symposium (SABCS)

SABCS Metastatic Breast Cancer Topic Screen

Independent Coverage of the 2007 San Antonio Breast Cancer Symposium

Normalization of N-telopeptide Associated with Improved Survival from Bone Metastasis Treated with Bisphosphonates (6/25/2008)
Researchers involved in a multicenter international trial have reported that normalization of N-telopeptide of type I collagen (NTX) levels is associated with skeletal-related events and survival among patients with bone metastases from solid tumors treated with Zometa® (zoledronic acid) or Aredia® (pamidronate). These results were published in the July 1, 2008 issue of Cancer.

Gemzar® Improves Survival in Early Pancreatic Cancer (6/9/2008)
Researchers from Germany have reported that adjuvant Gemzar® (gemcitabine) significantly improves disease-free and overall survival of patients with early pancreatic cancer. The details of this study were reported in a late-breaking abstract at the 2008 meeting of the American Society of Clinical Oncology May 30 to June 2 in Chicago.

Abraxane®/Gemzar® Promising in Pancreatic Cancer (4/24/2008)
Researchers from the Scottsdale Clinical Research Institute in Arizona have reported that Abraxane® (paclitaxel) and Gemzar® (gemcitabine) appeared promising for the treatment of advanced pancreatic cancer. These results were recently presented at the 2008 annual meeting of the American Association for Cancer Research, April 12-16, 2008 in San Diego.

Addition of Erbitux® Does Not Improve Outcomes in Pancreatic Cancer (4/14/2008)
Researchers from Italy have reported that the addition of Erbitux® (cetuximab) to Gemzar® (gemcitabine) and Platinol® (cisplatin) does not improve outcomes compared with chemotherapy only in advanced pancreatic cancer. These results were published in the January 2008 issue of Lancet Oncology.

Addition of Gemzar® in Early Pancreatic Cancer May Modestly Improve Survival (3/10/2008)
A multicenter U.S. and Canadian trial has shown that the addition of Gemzar® (gemcitabine) to 5-fluorouracil may modestly improve survival among patients undergoing surgery for early pancreatic cancer. The results of this Phase 3 randomized trial were published in the March 5, 2008 issue of the Journal of the American Medical Association.